<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889719</url>
  </required_header>
  <id_info>
    <org_study_id>SSC-0803</org_study_id>
    <nct_id>NCT01889719</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR</brief_title>
  <official_title>Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are&#xD;
      safe and whether they will boost immune responses generated by immunizations with a dendritic&#xD;
      cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are&#xD;
      safe and whether they will boost immune responses generated by immunizations with a dendritic&#xD;
      cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected&#xD;
      volunteers. Investigators propose to assess the quality of immunity elicited by immunizations&#xD;
      with MVA-CMDR only or by booster immunizations with MVA-CMDR in volunteers previously&#xD;
      immunized with a DC-targeted HIV vaccine. This vaccination regimen can provide the&#xD;
      proof-of-concept that DC targeted protein vaccines can prime strong immune responses and&#xD;
      therefore be valuable in combination with other vaccine modalities against HIV or other&#xD;
      diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of MVA-CMDR vaccine</measure>
    <time_frame>16 weeks</time_frame>
    <description>safety and tolerability of two intramuscular injections of MVA-CMDR vaccine candidate in healthy HIV-uninfected volunteers</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Vaccination with MVA-CMDR Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccination with MVA-CMDR Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-CMDR</intervention_name>
    <description>injections of MVA-CMDR vaccine</description>
    <arm_group_label>Vaccination with MVA-CMDR Group 1</arm_group_label>
    <arm_group_label>Vaccination with MVA-CMDR Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have completed protocol SSC-710 and received either DCVax-001 plus poly ICLC, poly&#xD;
             ICLC only or sterile saline. If less than 6 volunteers who originally received placebo&#xD;
             (poly ICLC only or sterile saline) under protocol SSC_710 are willing to participate&#xD;
             and are found eligible to participate in this proposed study, new volunteers can be&#xD;
             enrolled as long as they are eligible according to the remaining inclusion and&#xD;
             exclusion criteria below.&#xD;
&#xD;
          -  Healthy adult males and females, as assessed by a medical history, physical exam, ECG,&#xD;
             and laboratory tests;&#xD;
&#xD;
          -  Age of at least 18 years of age on the day of screening and no greater than 62 years&#xD;
             at time of vaccination;&#xD;
&#xD;
          -  Willing to comply with the requirements of the protocol and available for follow-up&#xD;
             for the planned duration of the study (screening plus 12 months);&#xD;
&#xD;
          -  In the opinion of the principal investigator or designee, has understood the&#xD;
             information provided. (Written informed consent needs to be given before any&#xD;
             study-related procedures are performed);&#xD;
&#xD;
          -  Amenable to HIV risk reduction counseling, committed to maintaining behavior&#xD;
             consistent with low risk of HIV exposure through the last required protocol clinic&#xD;
             visit;&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection on the basis of&#xD;
             sexual behaviors within the 12 months prior to enrollment defined as follows:&#xD;
&#xD;
          -  Sexually abstinent OR&#xD;
&#xD;
          -  Had two or fewer mutually monogamous relationships with partners believed to be&#xD;
             HIV-uninfected and who did not use illicit drugs (illicit drug use or abuse that&#xD;
             includes any injection drugs, methamphetamines (crystal meth), heroin, cocaine,&#xD;
             including crack cocaine or chronic marijuana abuse) OR&#xD;
&#xD;
          -  Had two or fewer partners believed to be HIV-uninfected and who did not use illicit&#xD;
             drugs (as defined above) and with whom he/she regularly used condoms for vaginal and&#xD;
             anal intercourse;&#xD;
&#xD;
          -  If sexually active female, willing to use one effective method of contraception&#xD;
             (combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine&#xD;
             Device (IUD); condoms; anatomical sterility in self or partner) at least until 3&#xD;
             months after last immunization. All female volunteers must be willing to undergo urine&#xD;
             pregnancy tests at time points as indicated in the Schedule of Procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed HIV-1 or HIV-2 infection&#xD;
&#xD;
          -  Any clinically significant abnormality on history or examination including history of&#xD;
             immunodeficiency or autoimmune disease; use of systemic corticosteroids&#xD;
             immunosuppressive anticancer, or other medications considered significant by the trial&#xD;
             physician within the last 6 months&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition requiring care of a&#xD;
             physician (e.g., diabetes, coronary artery disease, myopericarditis, grand-mal&#xD;
             epilepsy, rheumatologic illness, malignancy, substance abuse) that in the opinion of&#xD;
             the investigator would preclude participation&#xD;
&#xD;
          -  History of clinically significant eczema or chronic urticaria&#xD;
&#xD;
          -  Any laboratory value outside of reference range, with the exception of any&#xD;
             non-clinically significant Grade I elevations of liver function tests (AST, ALT,&#xD;
             direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined&#xD;
             by the Principal Investigator or his designee&#xD;
&#xD;
          -  Baseline ECG with features that would interfere with interpretation of&#xD;
             myo/pericarditis including significant repolarization abnormality, bundle branch&#xD;
             block, and AV block&#xD;
&#xD;
          -  Within the 12 months prior to enrollment, the volunteer has had excessive daily&#xD;
             alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of&#xD;
             illicit drugs&#xD;
&#xD;
          -  Within the 12 months prior to enrollment, the volunteer has a history of&#xD;
             newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus&#xD;
             type 2 (HSV2), pelvic inflammatory disease (PID), mucopurulent cervicitis,&#xD;
             epididymitis, proctitis, lymphogranuloma venereum, chancroid, hepatitis B (surface&#xD;
             antigen, HbsAg) or hepatitis C (HCV antibodies);&#xD;
&#xD;
          -  If female, pregnant, planning a pregnancy during the 3-month follow up period after&#xD;
             last immunization, or lactating&#xD;
&#xD;
          -  Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days&#xD;
             prior to study vaccination&#xD;
&#xD;
          -  Prior use of medications for HIV PrEP&#xD;
&#xD;
          -  Receipt of an investigational product (not vaccine-related) within the last 12 months.&#xD;
             Receipt of a non-HIV experimental vaccine(s) within the last 5 years in a prior&#xD;
             vaccine trial. Exceptions may be made for vaccines that have subsequently undergone&#xD;
             licensure by the FDA. For subjects who have received control/placebo in an&#xD;
             experimental vaccine trial, or who have received an experimental vaccine(s) greater&#xD;
             than 5 years ago, eligibility for enrollment will be determined by the investigators&#xD;
             on a case-by-case basis.&#xD;
&#xD;
          -  History of severe local or systemic reaction to vaccination defined as:&#xD;
&#xD;
          -  Local: extensive, indurated redness and swelling involving most of the major&#xD;
             circumference of the arm, not resolving within 72 hours;&#xD;
&#xD;
          -  Systemic: fever &gt; 39.5Â°C within 48 hours, anaphylaxis, bronchospasm, laryngeal edema,&#xD;
             circulatory collapse, convulsions or encephalopathy within 72 hours&#xD;
&#xD;
          -  History of immediate type hypersensitivity reaction to eggs or egg products&#xD;
&#xD;
          -  Major psychiatric illness&#xD;
&#xD;
          -  In the opinion of the investigator, unlikely to comply with protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Schlesinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller Univesrity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Prevention</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

